Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 17, 2025
Daily News
June 17, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
- Astellas, MRI Join Hands to Support Startups via MEDISO
June 17, 2025
- Maruishi Takes Over Bayer’s Sleep Inducer Evamyl in Japan
June 17, 2025
- 84% of Pharmacies See More Generic Dispensing after Rollout of New LLP Rule: FPMAJ
June 17, 2025
- FPMAJ Calls for Relaxation of Support Rules for Low-Priced Drugs
June 17, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…